IQVIA
About: IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Employees: 88,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.11% less ownership
Funds ownership: 84.74% [Q3] → 84.64% (-0.11%) [Q4]
6% less funds holding
Funds holding: 1,044 [Q3] → 986 (-58) [Q4]
17% less capital invested
Capital invested by funds: $36.5B [Q3] → $30.2B (-$6.34B) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 324 | Existing positions reduced: 421
24% less first-time investments, than exits
New positions opened: 129 | Existing positions closed: 169
29% less funds holding in top 10
Funds holding in top 10: 14 [Q3] → 10 (-4) [Q4]
36% less call options, than puts
Call options by funds: $165M | Put options by funds: $260M
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$160
3%
upside
Avg. target
$223
44%
upside
High target
$270
74%
upside
10 analyst ratings
7 positive
70%
3 neutral
30%
0 negative
0%
HSBC Rajesh Kumar 50% 1-year accuracy 2 / 4 met price target | 3%upside $160 | Hold Downgraded | 25 Apr 2025 |
Truist Securities Jailendra Singh 34% 1-year accuracy 12 / 35 met price target | 39%upside $216 | Buy Maintained | 10 Apr 2025 |
Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target | 10%upside $170 | Equal-Weight Downgraded | 10 Apr 2025 |
Mizuho Ann Hynes 57% 1-year accuracy 12 / 21 met price target | 35%upside $210 | Outperform Maintained | 9 Apr 2025 |
Citigroup Patrick Donnelly 27% 1-year accuracy 8 / 30 met price target | 35%upside $210 | Neutral Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 6 articles about IQV published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
2 days ago
IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Marie E. Lamont, head of Real World Solutions (Patient Insights, Experience and Registry Solutions), and Dr. Joanne Hackett, vice president, Health System Services (Europe, Middle East, Africa and South Asia), have been honored by the Healthcare Businesswomen.
Neutral
Business Wire
1 week ago
IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group® has named IQVIA a “front-runner generative AI leader” for the life sciences industry in its recent report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.” IQVIA was the only clinical research organization to receive the.
Neutral
Business Wire
1 week ago
IQVIA to Announce First-Quarter 2025 Results on May 6, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slid.
Neutral
Business Wire
2 weeks ago
Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--The life sciences innovation ecosystem continued to evolve and expand in 2024 as the industry continued to adapt to a complex and dynamic range of geopolitical, technological and social uncertainties. The year saw progress in funding, trial starts, program productivity and cycle times, according to the new report, Global Trends in R&D 2025: Progress in Recapturing Innovation in Biopharma Innovation, released by the IQVIA Institute for Human Dat.
Positive
Zacks Investment Research
2 weeks ago
IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?
IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Zacks Investment Research
1 month ago
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.
Neutral
Business Wire
1 month ago
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when s.
Positive
Zacks Investment Research
1 month ago
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.
Neutral
Business Wire
1 month ago
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites. At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows investigator sites to submit requisitions and manage lab specimens electronically, eli.
Charts implemented using Lightweight Charts™